undamentalytics Newsletter
Sign in

Bionexus Gene Lab Corp key statistics and ratios

In fiscal 2025, Bionexus Gene Lab Corp had return on equity of -35.2% and a net margin of -40.2%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin12.5%−194.1%9.6%5.6%−3.3%−26.9%−16.8%−40.2%−82.4%
Return on equity1.7%−18.6%28.1%10.9%−5.1%−32.2%−17.8%−35.2%−31.4%
Return on assets1.6%−17.1%19.3%7.6%−3.9%−26.1%−14.6%−30.3%−28.6%
Effective tax rate———−27.9%—————
R&D as % of revenue—————0.6%0.5%0.7%1.7%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $9m
Short-term assets $5mLonger-term assets $4m
What it owes, and who funded it · $9m
Short-term liabilities $1mLonger-term liabilities $0mShareholders' equity $8m
  • Short-term assets cover short-term liabilities $5m of assets due within a year against $812,938 of liabilities due within a year.
  • Short-term assets cover long-term liabilities $5m short-term assets against $135,043 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Bionexus Gene Lab Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

23 /100

Weak moat

How hard Bionexus Gene Lab's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -12.9% of total assets over 8 years.

  • Pricing power 7 / 20

    Gross margin has been a median 14.2%, moving by 2.8 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -13.8%; its worst year was -164.4%.

  • Cash conversion 5 / 20

    Free cash flow was positive in 4 of 8 years, at a median -11.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (28 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BGLC vs QSIBGLC vs SEERBGLC vs YDES

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bionexus Gene Lab Corp's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bionexus Gene Lab Corp.